Press Releases Ypsomed Group

Burgdorf - Ypsomed has a general policy not to comment on stock price developments or rumours. Due to a enquiries from investors and press representatives, however, Ypsomed considers it important to make the following statements.

Press Releases Ypsomed Group

Burgdorf - In the 2004/05 business year Ypsomed achieved new highs in terms of sales, profit and investments. The Ypsomed Group's consolidated sales rose 21.7% to CHF 241.8 million. In the core business (pen systems, pen needles and Ypsotec) sales even increased by 42.8%. Particularly pleasing was a 157.8% rise in operating profit to CHF 47.5 million, representing an operating profit margin of 19.7%.

Press Releases Ypsomed Group

Burgdorf - Ypsomed AG in collaboration with Safety Syringes, Inc. has designed a reusable Autoinjector specifically for use with the UltraSafe Drug Delivery Systems by Safety Syringes, Inc.

Press Releases Ypsomed Group

Burgdorf - Ypsomed, the leading independent developer and manufacturer of custom-made injection pens for pharmaceutical and biotech companies, and one of the leading suppliers of pen needles, is focusing future investments on its core business.

Press Releases Ypsomed Group

Burgdorf - OptiClik, developed and manufactured by Ypsomed, is the first "semi-disposable" insulin pen-system now launched by Sanofi-Aventis for its long-acting insulin Lantus in the US market. The market launch of OptiClik is a major milestone within Ypsomed's growth strategy.